MedTrace Logo

Higher Dose of Alglucosidase Alpha for Pompe Disease

NCT05017402 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 36

Last updated 2021-08-23

No results posted yet for this study

Summary

This study is aimed to investigate that whether the higher dose ERT improve safety and clinical outcomes of Pompe disease patients. Also, wish to develop a new therapeutic recommendation and hope that it could improve the long-term outcomes of Pompe diesease patients.

Conditions

  • Glycogen Storage Disease Type II

Interventions

DRUG

Alglucosidase Alfa

Standard dose: 20-25 mg/kg every other week; Higher dose: \>25 mg/kg every other week.

Sponsors & Collaborators

  • Taipei Veterans General Hospital, Taiwan

    lead OTHER_GOV

Eligibility

Min Age
0 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-01
Primary Completion
2023-12-31
Completion
2026-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05017402 on ClinicalTrials.gov